Wang, Yen-Feng
Tzeng, Yi-Shiang
Yu, Chia-Chun
Ling, Yu-Hsiang
Chen, Shih-Pin
Lai, Kuan-Lin
Chen, Wei-Ta
Wang, Shuu-Jiun
Funding for this research was provided by:
Taiwan National Science and Technology Council (109-2314-B-075 -054 and 110-2314-B-075 -041 -MY3, 104-2314-B-010-015-MY2, 106-2321-B-010-009, 107-2321-B-010-001, 108-2321-B-010-014 -MY2, 108-2321-B-010 001, 108-2314-B-010-023-MY3, and 110-2321-B-010-005)
Taipei Veterans General Hospital (V108C-092, V109C-096, V110C-111, V111C-161, V112C-078, and V112D67-003-MY3-1)
Article History
Received: 3 September 2023
Accepted: 24 October 2023
First Online: 1 November 2023
Declarations
:
: The study protocols were approved by the Institutional Review Board of Taipei Veterans General Hospital (VGH IRB No. 2018–07-020BC, and 2019–07-002CC).
: Not applicable.
: Y.F.W. has received honoraria as a speaker from Taiwan branches of Allergan/AbbVie, Boehringer Ingelheim, Chugai, Eli Lilly, Novartis, Pfizer, Sanofi, UCB, and Viatris, Hava Bio-Pharma, Orient EuroPharma, and Teva. He has received research grants from the Taiwan National Science and Technology Council (formerly Taiwan Ministry of Science and Technology), and Taipei Veterans General Hospital. S.J.W. has served on the advisory boards of Daiichi-Sankyo, Eli Lilly and Novartis; has received honoraria as a moderator from Allergan/AbbVie, Pfizer, Eli Lilly, Biogen and Eisai and has been the PI in trials sponsored by Eli Lilly, Novartis, and Allergan/AbbVie. He has received research grants from the Taiwan National Science and Technology Council (formerly Taiwan Ministry of Science and Technology); Brain Research Center, National Yang Ming Chiao Tung University from The Featured Areas Research Center Program within the framework of the Higher Education Sprout Project by the Taiwan Ministry of Education; Taipei Veterans General Hospital; Taiwan Headache Society; and Taiwan branches of Eli Lilly, Novartis, and Pfizer. Y.S.T, C.C.Y., Y.H.L., S.P.C, K.L.L., and W.T.C. reported no relevant conflict of interest.